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A B S T R A C T   
Background and aims: A first-time acute myocardial infarction (AMI) is a severe diagnosis that leads to initiation 
or intensification of lipid-lowering medication to prevent recurrent events. Individuals with familial hypercho-
lesterolemia (FH) already use high-intensity lipid-lowering medication at the time of an incident AMI due to their 
diagnosis. Hence, we hypothesized that compared with matched non-FH controls, individuals with genetically 
verified FH have increased mortality and risk of recurrent AMI after their first event. 
Methods: The study population comprised 4871 persons with genetically verified FH, and 96,251 age and sex 
matched controls randomly selected from the Norwegian population. Data were obtained from the Cardiovas-
cular Disease in Norway Project, the Norwegian Patient Registry and the Norwegian Cause of Death Registry. 
Incidence of AMI, all-cause mortality and recurrent AMI after incident AMI were analyzed for the period 
2001–2017. Incidence and mortality were compared using hazard ratios (HR) from Cox regression. Risk of 
recurrent AMI was compared using sub-hazard ratios (SHR) from competing risk regression with death as a 
competing event. 
Results: We identified 232 individuals with FH and 2118 controls with an incident AMI [HR 2.10 (95% CI 
1.83–2.41)]. Among survivors ≥29 days after the incident AMI, both mortality [HR = 1.45 (95% CI: 1.07–1.95)] 
and recurrent AMI [SHR = 2.53 (95% CI: 1.88–3.41)] were significantly increased among individuals with FH 
compared with non-FH controls. 
Conclusions: Individuals with FH have increased mortality and increased risk of recurrent AMI after the first AMI 
event compared with controls. These findings call for intensive follow-up of individuals with FH following an 
AMI.   
1. Introduction 
Familial hypercholesterolemia (FH) is an inherited disorder esti-
mated to affect an average of 1:300 [1]. FH is usually caused by a mu-
tation in the low-density lipoprotein (LDL) receptor gene resulting in 
high circulating levels of LDL-cholesterol (LDL-C) from birth [2,3]. Ideal 
treatment in FH includes lifelong lipid-lowering treatment [4] and 
observational data on statin therapy initiated in childhood has shown to 
slow the progression of atherosclerosis and reduce the risk of coronary 
heart disease (CHD) after 20 years of follow-up [5]. Individuals with 
genetically verified FH have increased risk of suffering from an early 
incident acute myocardial infarction (AMI) event or premature death 
compared with the general population [6]. After the first AMI, in-
dividuals with possible or probable FH have increased risk of combined 
cardiovascular disease (CVD) endpoint (death, AMI or stroke) or 
recurrent AMI after ≤5 years of follow-up [7,8]. However, as CVDs differ 
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in severity and treatment, risk of mortality and recurrent AMI after the 
first event should be analyzed separately from other CVDs. With the 
present study, we aimed to strengthen existing findings by comparing 
the risk of incident and recurrent AMI and mortality after the incident 
AMI between individuals with genetically verified FH and age and sex 
matched controls during 2001-2017. 
2. Materials and methods 
2.1. Study population 
This is a prospective matched cohort study comprising individuals 
with genetically verified FH and age and sex matched non-FH controls 
obtained from the general population. The FH population was obtained 
from the Unit for Cardiac and Cardiovascular Genetics (UCCG) database 
at Oslo University Hospital, where all individuals with FH are included 
after genetic diagnosis and after obtaining written informed consent [3, 
10]. In Norway, the majority of individuals with genetically verified FH 
are identified through cascade screening, meaning that the relatives of 
an index patient are tested for different FH mutations [3,10]. 
In the present study, we included a cohort of 5635 individuals who 
were genetically diagnosed with FH between January 1, 1992 and 
March 1, 2014 (deadline of inclusion to the main study). Of these, we 
were missing exact inclusion date and hence the date of genetically 
verified FH diagnosis in 744 individuals who were diagnosed prior to 
1992. These individuals were assigned the inclusion date January 1, 
1992, as previously described [10]. For each individual with FH, 20 
controls living in Norway in the same time period were matched ac-
cording to sex and age, yielding a non-FH control sample of 112,589 
individuals. This inclusion of a matched control sample was performed 
as an overall goal to study risk of several diseases including cancer [10]. 
In the present study, we excluded 764 individuals with FH and 16,338 
controls who either had been hospitalized with AMI or were deceased 
before study start or who were <20 years of age before study end 
(December 31, 2017). For the control cohort, we also excluded those 
who, after exclusion of individuals in the FH population, were no longer 
matched to an individual with FH. Hence, the final sample for analysis of 
incident AMI consisted of 4871 individuals with FH and 96,251 age and 
sex matched controls (Fig. 1). 
During the follow-up time 2001–2017, out of 232 cases of incident 
AMI in the FH cohort and 2118 in the control cohort, 221 and 1947 cases 
(no longer matched) were hospitalized with AMI and were included for 
analysis of mortality, whereas risk of recurrent AMI was investigated in 
190 and 1666 survivors, respectively, who were still alive ≥29 days after 
discharge from incident AMI hospitalization (Fig. 1). 
2.2. Registry linkages 
Information on incident and recurrent AMI and mortality after AMI 
from 2001 through 2017 was obtained by linking each individual’s 
unique personal identification number to the following databases and 
registries: The Cardiovascular Disease in Norway Project (CVDNOR) at 
the University of Bergen (hospitalization data from 1994 through 2007) 
[11,12], the Norwegian Patient Registry (hospitalization data from 2008 
through 2017), and the Norwegian Cause of Death Registry (date and 
cause of death from 1992 through 2017) (Fig. 2). Endpoints were 
defined according to the International Classification of Diseases (ICD), 
version 9 (ICD-9) and version 10 (ICD-10). An incident case of AMI was 
defined as a hospitalization with AMI (ICD-9: 410, ICD-10: I21, I22) as 
main or secondary discharge diagnosis, or as the underlying cause of 
death without prior AMI events. 
As illustrated in Fig. 2, in order to allow at least 7 years of look-back 
for previous events, we used data for the period 1994–2000 as washout, 
and analyzed incidence of AMI [13] for the period 2001–2017. Within 
Fig. 1. Flow chart of inclusion and exclusion of individuals in the main study and individuals available for analysis of incidence, mortality and re-hospitalization of 
AMI in FH and controls. 
AMI, acute myocardial infarction; FH, familial hypercholesterolemia. 
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each case set, the start of follow-up was defined as the latest date of the 
following three dates: the registration date in the UCCG Registry for the 
FH diagnosis, January 01 in the year the person reached age 20, or 
January 01, 2001. All individuals were followed until their first AMI, 
death or December 31, 2017 (study end), whichever occurred first. 
2.3. Mortality 
In analyses of all-cause mortality after AMI, we included individuals 
who were hospitalized with an incident AMI. Follow-up was measured 
from the date of hospitalization until death or December 31, 2017, 
whichever occurred first. We further split the follow-up period into 
short-term (0–28 days) and long-term (≥29 days) mortality among 
survivors. 
2.4. Recurrent acute myocardial infarction 
Recurrent AMI was calculated as time from day 29 after discharge of 
incident AMI and until a new hospitalization with AMI as primary or 
secondary diagnosis, death, or December 31, 2017, whichever occurred 
first. Any re-hospitalizations of AMI occurring 0–28 days after incident 
AMI were considered part of the initial AMI and not a new event. 
2.5. Approvals 
The Regional Committee of Medical and Health Research Ethics 
South-Eastern Norway approved the study (reference 2011/1343 REK 
Sør-Øst B). The study was granted exemption from the obligation to 
obtain informed consent, as previously described [10]. The study com-
plies with the Declaration of Helsinki and was reported to the Norwegian 
Data Protection Official at Oslo University Hospital. 
2.6. Statistics 
Incidence of AMI was compared between individuals with FH and 
the controls using cumulative incidence plots obtained using the 
stcompet-package in Stata with age as the time scale and hazard ratios 
(HR) from Cox proportional hazards regression. We also performed Fine 
& Gray competing risk regression with death from other causes than AMI 
treated as competing events, which yielded similar results. We therefore 
chose to only present HRs from Cox regression in analyses of incidence 
of AMI. All-cause mortality among individuals hospitalized for incident 
AMI (the FH and control populations were no longer matched) was 
analyzed using Cox regression with follow-up measured from the date of 
hospitalization until death or December 31, 2017, whichever occurred 
first. Results were split into short-term and long-term mortality rates 
among survivors on day 28. HRs in main analyses were adjusted for age 
and sex. In additional analyses, we also adjusted for comorbidities (heart 
failure, atrial fibrillation, hypertension, diabetes and stroke) reported 
during the incident AMI hospitalization. Among the survivors, risk of 
recurrent AMI was analyzed using competing risk regression with death 
treated as competing event and reported as sub-hazard ratios (SHR), 
adjusted for age. All results were stratified on sex, and all analyses were 
performed with Stata version 15. 
3. Results 
The sex distribution in the initial matched study populations was 
47% men and 53% women, with a mean age at start of follow-up for 
analysis of incident AMI of 38.4 ± 15.9 years in FH and 38.1 ± 15.7 
years in controls. 
In total, 232 cases of incident AMI were registered in the FH popu-
lation and 2118 cases in the control population. The FH population had a 
2-fold increased risk of incident AMI compared with controls [HR 2.10 
(95% CI: 1.83–2.41)] with similar excess risk in men [HR 2.20 (95% CI: 
1.85–2.61)] and women [HR 1.95 (95% CI: 1.55–2.44)]. The cumulative 
incidences of AMI in the FH population were higher than in the control 
population for both men and women in all ages as illustrated in Fig. 3. 
Among those with incident AMI, 221 in the FH population and 1947 
controls were hospitalized for AMI, with a mean age at hospitalization of 
60.5 ± 15.4 years in FH, and 65.3 ± 12.4 years in controls. 
3.1. Mortality 
Among the 221 and 1947 individuals hospitalized with AMI, 63 in-
dividuals (28.5%) with FH and 531 controls (27.2%) died during the 
follow-up period (2001–2017), yielding a HR of 1.32 (95% CI: 
1.01–1.71), adjusted for age and sex. The excess mortality was higher in 
men with FH [HR adjusted for age 1.44 (95%: CI 1.0–2.07)] whereas the 
corresponding age-adjusted HR in women was 1.20 (95%: CI 
0.81–1.76). 
After further adjustment for comorbidities reported during the inci-
dent AMI hospitalization (heart failure, atrial fibrillation, hypertension, 
diabetes and stroke), the HR for the total population was reduced to 1.27 
(95% CI: 0.98–1.65). The main cause of death was CHD in both groups; 
34.5% in the FH population and 32.6% in controls. 
As shown in Fig. 4, the increased mortality in the FH population was 
present in the long-term (≥29 days) and not significantly different in the 
Fig. 2. Individuals with FH registered in the Unit for Cardiac and Cardiovascular Genetics Registry between 1992 and 2014 were obtained through registry linkage 
from 1992 through 2017. 
In order to have at least 7 years of washout for previous events prior to start of follow-up for everyone, we analyzed incidence of AMI for the period 2001– 
2017. AMI, acute myocardial infarction; FH, familial hypercholesterolemia; CVDNOR, The Cardiovascular Disease in Norway Project; NPR, The Norwegian Pa-
tient Registry. 
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short-term (0–28 days) follow-up after hospitalization with incident 
AMI. 
Twenty-nine or more days after being hospitalized with incident 
AMI, the FH population had a 45% increased mortality compared with 
controls [age and sex adjusted HR 1.45 (95% CI: 1.07–1.95)], with 
similar increased risk among men and women with FH. After further 
adjustment for the comorbidities reported during hospitalization, the 
excess mortality in FH was reduced, but it was still significantly higher 
than in controls [HR 1.38 (95% CI: 1.02–1.86)]. 
3.2. Recurrence of acute myocardial infarction 
In total, 30% (n = 57) of those who survived the first 28 days after 
discharge for incident AMI in the FH population were re-hospitalized 
with recurrent AMI after ≥29 days during the follow-up period. In 
comparison, only 15% (n = 248) of non-FH controls experienced a 
recurrent AMI during the same period. These numbers correspond to a 
2.5-fold increased risk of recurrent AMI among individuals with FH 
compared with controls [SHR 2.53 (95% CI: 1.88–3.41)] after adjust-
ment for age and sex. Further adjustment for comorbidities reported 
during the hospitalization for incident AMI did not reduce the increased 
Fig. 3. Cumulative incidence of acute myocardial infarction (AMI) during 2001–2017 for the familial hypercholesterolemia (FH) cohort and the control cohort with 
age as the timescale. 
Fig. 4. Risk of short-term (0–28 days) and long-term mortality (≥29 days) after incident AMI presented as age adjusted HR in individuals with FH versus controls. 
AMI, acute myocardial infarction; FH, familial hypercholesterolemia. HR; hazard ratio. 
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risk [SHR 2.63 (95% CI: 1.95–3.54)]. This increased risk in FH was 
similar among men and women with FH (Table 1). 
4. Discussion 
In this large prospective cohort study, we found that after an incident 
AMI, the long-term mortality was increased by 45%, and the risk of 
recurrent AMI was 2.5-fold increased during 17 years of follow-up in 
individuals with genetically verified FH compared with controls. 
These results in 232 individuals with genetically verified FH who had 
experienced a first-time AMI support and extend (with 17 years of 
follow-up) previous results in individuals with probable FH [7,8,14–19]. 
Rerup and co-workers found that individuals with probable FH had a 
1.28-fold increased risk of recurrent AMI after a median of 3.3 years of 
follow-up [8], whereas Danchin and co-workers found a 2.2-fold 
increased risk of the combined outcome death or recurrent major car-
diovascular events after 5 years of follow-up in probable FH [7]. Several 
other studies also report increased risk of recurrent CVD in individuals 
with clinical/possible FH compared with non-FH individuals with a 
follow-up time of at least one year [14–19]. However, it should be noted 
that due to their diagnosis, individuals with FH are more likely to have 
been frequently followed up by their general physicians and at lipid 
clinics compared with controls. Increased risk of hospitalization with 
less acute CVD diagnoses among individuals with FH after an incident 
AMI could therefore reflect increased follow-up and treatment. This kind 
of treatment bias cannot explain the observed increased risk of recurrent 
acute events like AMI reported in the present study. Furthermore, clas-
sifying FH according to the Simone Broome Register criteria [18], the 
definition by the American Heart Association [17] and the Dutch Lipid 
Clinic definition [19] yield different prevalence of FH, and accordingly 
less comparable risk estimates. Our results on genetically verified FH are 
therefore needed to verify previous findings. 
The increased risk of recurrent AMI in FH is observed in a time period 
with widespread use of statins among individuals with genetically 
verified FH [20,21]. We did not have information on the use of 
lipid-lowering medication in the present study. However, it is reason-
able to assume that most of the individuals with FH already used 
lipid-lowering medication when experiencing their first-time AMI, since 
all had been genetically diagnosed at the start of follow-up. In a study of 
Norwegian individuals with FH by Bogsrud and co-workers, 89% of 
those visiting lipid clinics were prescribed statins, and in those at high 
risk, the prevalence was 93% [20]. A recent Norwegian study demon-
strated that among young individuals (<45 years) hospitalized with 
AMI, statins were reported to be used by 63% among those who had FH 
and 29% of those without FH at admission [22]. After an incident AMI, 
the statin dose in most individuals with FH will be increased if they are 
not already using potent statins. However, intensifying the dose or type 
of statins only reduces LDL-C levels to a certain extent, as demonstrated 
in a subpopulation of the current population where the LDL-C treatment 
goal was only achieved by 25% of the subjects with FH at normal risk, 
and 8% with very high risk [20]. Hence, little can be done to further 
reduce AMI risk and LDL-C levels in individuals with FH without add-on 
proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. 
Accordingly, with little or no further reduction post AMI, the mean 
on-treatment LDL-C level in individuals with FH would remain at 3–4 
mmol/L despite receiving a maximally accepted dose of statin therapy 
with or without ezetimibe [20,23]. On the other hand, individuals 
without FH, who mostly have not received statins before their incident 
AMI [22], will be prescribed potent statins immediately after AMI, 
which would reduce their LDL-C levels significantly [4,24]. In this way, 
the controls in this study would have a major reduction in their LDL-C 
levels following the incident AMI, whereas the FH population would 
have little (or no) change in their LDL-C levels. In sum, this is likely to 
have impact on the increased risk of recurrent AMI and mortality seen in 
the FH population. 
Different lifestyle factors such as smoking and poor diet are known 
risk factors for CVD [4]. The Norwegian FH population is, however, 
characterized by fewer smokers and healthier lifestyle and diet than 
non-FH individuals [25], as also discussed in our recent publication on 
cancer risk in the same cohort of individuals with FH [10]. In the present 
study, we do not know the smoking prevalence in those who experienced 
an AMI, but the previous publications from the same FH cohort [4,25] 
suggest that smoking and other lifestyle factors are less likely to have 
contributed to the increased risk of recurrent AMI seen in this FH pop-
ulation here. On the contrary, if we had been able to adjust for smoking 
in the analyses, the data suggest that the HR could have been even 
higher. 
Several other primary CVD risk factors might have contributed to the 
increased risk in FH observed post AMI [6,26]. Diabetes increases the 
risk of death or recurrent AMI after the first event [27,28]. However, 
among the hospitalized cases in this study, the proportions with diabetes 
and hypertension at the time of the incident AMI were non-significantly 
lower among individuals with FH compared with controls, and the 
proportions with heart failure, atrial fibrillation and stroke were similar 
among individuals with and without FH (Supplementary file 1). 
Furthermore, adjusting for the comorbidities did not significantly 
impact the mortality rate nor the risk of recurrent AMI, and our findings 
therefore suggest that the higher mortality rate and risk of recurrent AMI 
in this FH population after incident AMI cannot be explained by a higher 
level of some of the most important comorbidities at the time of incident 
AMI. We cannot however rule out that individuals with FH have a poorer 
health status or experience a more severe first-time AMI than non-FH 
individuals which again could have impacted their increased risk of 
mortality and recurrent AMI. Unfortunately, we did not have data on 
indicators of severity of AMI in this study. Still, for men we did observe a 
HR for short-term mortality of 1.51 (95% CI: 0.95–2.22), which could 
indicate increased mortality in the acute phase in men. However, the 
result was not significant, and has to be interpreted with caution. 
Not surprisingly, the doubled risk of incident AMI in individuals with 
genetically verified FH compared with age and sex matched controls 
Table 1 
Re-hospitalization with acute myocardial infarction (AMI) among those who survived the first 28 days after an incident AMI hospitalization during 2001–2017, in a 
population with familial hypercholesterolemia (FH) versus controls.   
Survivors to day 
28 




Incidence rate per 1000 person years 
(95% CI) 
SHR re-hospitalization (95% 
CI)a 
Total study population 
Controls 1666 248 8.1 30.5 (26.9–34.5) 1 
FH 190 57 0.8 69.4 (53.5–90.0) 2.53 (1.88–3.41) 
Women 
Controls 616 98 2.8 34.8 (28.6–42.5) 1 
FH 67 19 0.3 68.9 (43.9–108.0) 2.24 (1.35–3.69) 
Men 
Controls 1050 150 5.3 28.2 (24.0–33.1) 1 
FH 123 38 0.6 69.7 (50.7–95.7) 2.68 (1.85–3.87)  
a Sub hazard ratio (SHR) from competing risk regression. 95% CI; 95% confidence interval. FH; familial hypercholesterolemia. AMI; acute myocardial infarction. 
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from 2001 through 2017, supports and extends previous findings [6,21]. 
However, with respect to the large number of undiagnosed individuals 
with FH, this is of concern. Only 1/3 of those estimated to have FH in 
Norway have currently been diagnosed [29], and the risk of incident 
AMI in non-diagnosed and untreated individuals with FH is likely to be 
considerably higher. This is illustrated by the recent finding that among 
young (<45 years) individuals hospitalized with AMI, 3% of the total 
population (or 21% of those actually tested) had genetically verified FH 
[22]. Taken together, our results suggest that the severity and conse-
quences of having an FH diagnosis (and probably with an insufficient 
treatment of individuals with FH) are likely to have impacted on the 
increased risk of incident and recurrent AMI, in addition to the increased 
mortality in individuals with FH, compared with non-FH controls. 
There are several strengths of the study. First, all individuals with FH 
included in the study have genetically verified FH, obtained from one of 
the largest national FH cohorts in the world [3,9]. The study includes 20 
controls per individual with FH who were matched on age and sex, and 
the follow-up time is long (2001–2017 with additional 7 years of 
wash-out). FH is inherited from heterozygous parents across socioeco-
nomic strata. Therefore, there is no need to adjust for socioeconomic 
status. We obtained the endpoints from national population-based reg-
istries with a long follow-up time, which ensures an almost complete 
follow-up. Information on date and cause of death made it possible to 
consider death as a competing event in analyses of risk of incident and 
recurrent AMI. 
Limitations include the lack of details on lifestyle, biochemical 
measures of LDL-C and other risk factors, smoking history and use of 
lipid-lowering medication. Furthermore, the matching of controls to the 
FH population was performed with the aim of studying the risk of 
incident AMI. Since individuals with FH experience their first AMI at a 
younger age compared with controls, the two groups were not matched 
in analyses of survival after AMI and risk of recurrence. To account for 
this, we adjusted for age and sex, and also for various comorbidities in 
additional analyses. There could be other important unmeasured dif-
ferences between the individuals with FH and controls at the time of 
incident AMI. We cannot rule out that the observed increased risk of re- 
hospitalization could at least partly be caused by other factors than an 
FH mutation. In addition to the matching, there might also be unknown 
selection bias towards the population being studied because the current 
sample does not necessarily reflect the total population of individuals 
with FH in Norway due to the possible high number of undiagnosed 
individuals with FH [29]. The lack of active consent and hence the low 
reservation rate to the present study (2.5%) [10], however, strengthens 
the generalizability of the results. 
In summary, our results demonstrate that during 17 years of follow- 
up, individuals with genetically verified FH have a more than doubled 
risk of both incident and recurrent AMI and increased mortality 
compared with non-FH controls. These findings therefore demonstrate a 
poorer prognosis after incident AMI in individuals with FH, under-
scoring the severity of the FH diagnosis and the need to monitor in-
dividuals with FH (even more) closely after their first AMI. 
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